Having trouble accessing articles? Reset your cache.

Attacking cancer's secretive side

Researchers from the Weizmann Institute of Science have shown that antibodies against epidermal growth factor receptor ligands from pancreatic tumors boosted the effectiveness of Eli Lilly and Co.'s Gemzar gemcitabine, one of the two drugs on the market approved as first-line therapies for the indication.1 The team thinks targeting tumor-specific epidermal growth factor receptor ligands is an approach that could extend to other cancers.

Seven small molecule and antibody antagonists of epidermal growth factor receptors (EGFRs) are approved for cancer (see "Suited to EGFR"). However, there are no disclosed therapies in clinical development targeting EGFR ligands, even though drugs that

Read the full 990 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers